Building the next generation of sustainable data centres in pharma
In the age of AI, pharma and tech companies are increasingly joining forces. Inevitably, such collaboration demands a strong digital…
22 Oct 2026
CPHI 2026: Pharma manufacturers put AI to work
Predictive maintenance, virtual process development, and artificial intelligence (AI)-assisted quality management are creating practical opportunities for pharmaceutical manufacturers. But the industry’s ability to scale these applications will depend less on…
22 Oct 2026
Podcast: The impact of prediction markets on the clinical sector
Publicly traded drug developers have been exposed to insider trading on their stocks for decades, but with the introduction of prediction markets in the clinical sector private companies are now…
12 Oct 2026
Women’s health landscape shifting, but systemic hurdles remain
It is no secret that research and development (R&D) efforts to improve care in women’s health have long been critically underfunded – with companies focused exclusively on women’s health attracting…
08 Oct 2026
Podcast: Key takeaways from EASD 2026 on where GLP-1s are headed
The world of diabetes and obesity research has exploded in recent years with the blockbuster success of glucagon-like peptide (GLP)-1 therapies and the rapid pace of innovation seen with next-generation…
05 Oct 2026
GLP-1RA non-responders: tackling a hidden challenge behind the obesity epidemic
In recent years, the notoriety and uptake of incretin-based therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) has skyrocketed, with drugs in this class making waves in both the public…
02 Oct 2026
Magazine: Keep it cool
Pharma is being pulled in every direction at once: more complex, more connected, more uncertain. Yet the industry keeps moving, and its momentum shows no sign of slowing. In this…